10 Product Filings Jobs

As a global integrated pharmaceutical company, Jubilant Pharma Limited offers a diverse range of products and services to customers worldwide. The business is structured into two main segments: Specialty Pharmaceuticals and Generics & APIs. Jubilant Generics (JGL), a subsidiary of Jubilant Pharma, has Research & Development units in Noida and Mysore, India, along with manufacturing facilities in Mysore, Karnataka, and Roorkee, Uttarakhand. The Mysore facility, spread across 69 acres, is a USFDA approved site primarily focused on manufacturing APIs for Lifestyle driven Therapeutic Areas such as CVS and CNS. The Roorkee facility is a state-of-the-art site approved by multiple regulatory bodies including USFDA, Japan PMDA, UK MHRA, TGA, WHO, and Brazil ANVISA, focusing on a B2B model for EU, Canada, and emerging markets. Both manufacturing units are supported by a team of around 500 research and development professionals based in Noida and Mysore. The R&D team is dedicated to developing new products in API, Solid Dosage Formulations, Sterile Injectable, Semi-Solids Ointments, Creams, and Liquids. The company conducts all BA/BE studies in-house at an 80 Bed facility with global regulatory accreditations. JGL's Regulatory Affairs & IPR professionals manage a unique portfolio of patents and product filings in both regulatory and non-regulatory markets. The company's revenue has shown consistent growth, reaching INR 53,240 Million during the Financial Year 2018-19, compared to INR 39,950 Million in the Financial Year 2017-18. For more information about Jubilant Pharma, please visit www.jubilantpharma.com.,

Jubilant Pharma Limited is a global integrated pharmaceutical company that offers a diverse range of products and services to customers worldwide. The business is structured into two main segments: Specialty Pharmaceuticals and Generics & APIs. Within Specialty Pharmaceuticals, Jubilant Pharma focuses on Radiopharmaceuticals, Contract Manufacturing of Sterile Injectable, Non-sterile & Allergy Therapy Products. In addition, the company is involved in Generics & APIs, including Solid Dosage Formulations & Active Pharmaceutical Ingredients. Jubilant Generics (JGL), a subsidiary of Jubilant Pharma, operates in India with Research & Development units located in Noida and Mysore. JGL has two manufacturing facilities in Mysore, Karnataka, and Roorkee, Uttarakhand, specializing in APIs and Dosage manufacturing. The Mysore manufacturing site, spread over 69 acres, is a USFDA approved facility focusing on APIs production and global sales. The API portfolio emphasizes on Lifestyle driven Therapeutic Areas such as CVS and CNS, targeting complex and newly approved molecules. Jubilant Pharma is a market leader in four APIs and among the top three players in another three APIs, maintaining a high contribution margin. The Roorkee manufacturing facility in Uttarakhand is a state-of-the-art site approved by multiple regulatory bodies including USFDA, Japan PMDA, UK MHRA, TGA, WHO, and Brazil ANVISA. This facility operates on a B2B model, catering to the EU, Canada, and emerging markets. Both manufacturing units are backed by approximately 500 research and development professionals based in Noida and Mysore. The R&D team is dedicated to developing new products in APIs, Solid Dosage Formulations of Oral Solid, Sterile Injectable, Semi-Solids Ointments, Creams, and Liquids. The company's 80-bed facility conducts all BA/BE studies in-house, holding approvals and certifications from various regulatory authorities globally. JGL's full-fledged Regulatory Affairs & IPR professionals manage a unique portfolio of patents and product filings in regulatory and non-regulatory markets. Jubilant Pharma has shown consistent revenue growth, with revenue reaching INR 53,240 Million during the Financial Year 2018-19, compared to INR 39,950 Million in the Financial Year 2017-18. For more information about the organization, please visit www.jubilantpharma.com.,

Jubilant Pharma Limited is a global integrated pharmaceutical company offering a wide range of products and services to customers across different geographies. The business is structured into two main segments: Specialty Pharmaceuticals and Generics & APIs. Specialty Pharmaceuticals includes Radiopharmaceuticals, Contract Manufacturing of Sterile Injectable, Non-sterile & Allergy Therapy Products. Generics & APIs include Solid Dosage Formulations & Active Pharmaceutical Ingredients. Jubilant Generics (JGL) is a wholly-owned subsidiary of Jubilant Pharma with Research & Development units in Noida and Mysore, India. The company operates manufacturing facilities in Mysore, Karnataka, and Roorkee, Uttarakhand, focusing on APIs and Dosage manufacturing. The Mysore manufacturing site, spread over 69 acres, is USFDA approved and manufactures APIs targeting Lifestyle-driven Therapeutic Areas like CVS and CNS. It is a market leader in four APIs and among the top three players for another three APIs. The Roorkee facility is state-of-the-art and approved by USFDA, Japan PMDA, UK MHRA, TGA, WHO, and Brazil ANVISA, focusing on a B2B model for EU, Canada, and emerging markets. Both manufacturing units are backed by around 500 research and development professionals based at Noida and Mysore. The R&D team works on developing new products in API, Solid Dosage Formulations, Sterile Injectable, Semi-Solids Ointments, Creams, and Liquids. In-house BA/BE studies are conducted at an 80-bed facility with global regulatory accreditations. JGL's Regulatory Affairs & IPR professionals manage a unique portfolio of patents and product filings in regulatory and non-regulatory markets. Jubilant Pharma's revenue has been on a consistent growth trajectory, with INR 53,240 Million in the Financial Year 2018-19 compared to INR 39,950 Million in 2017-18. For more information about the organization, please visit www.jubilantpharma.com.,

Jubilant Pharma Limited is a global integrated pharmaceutical company that offers a diverse range of products and services to customers worldwide. The business is structured into two primary segments: Specialty Pharmaceuticals and Generics & APIs. Under Specialty Pharmaceuticals, the company specializes in Radiopharmaceuticals, Contract Manufacturing of Sterile Injectable, Non-sterile & Allergy Therapy Products. The Generics & APIs segment focuses on Solid Dosage Formulations & Active Pharmaceutical Ingredients. Jubilant Generics (JGL) serves as a wholly-owned subsidiary of Jubilant Pharma with Research & Development units located in Noida and Mysore, India. JGL operates manufacturing facilities in Mysore, Karnataka, and Roorkee, Uttarakhand, producing APIs and Dosage manufacturing, respectively. The Mysore manufacturing site, approved by USFDA, manufactures APIs targeting Lifestyle driven Therapeutic Areas such as CVS and CNS. It is a market leader in four APIs and among the top three players for three others. The Roorkee facility is a state-of-the-art site approved by multiple regulatory bodies including USFDA, Japan PMDA, UK MHRA, TGA, WHO, and Brazil ANVISA, focusing on a B2B model for EU, Canada, and emerging markets. Both manufacturing units are supported by a team of 500 research and development professionals based in Noida and Mysore. The R&D team is dedicated to developing new products in API, Solid Dosage Formulations of Oral Solid, Sterile Injectable, Semi-Solids Ointments, Creams, and Liquids. The in-house 80 Bed facility conducts all BA/BE studies and holds certifications from various global regulatory authorities. JGL's Regulatory Affairs & IPR professionals manage a unique portfolio of patents and product filings in both regulatory and non-regulatory markets. The company has shown consistent revenue growth, with INR 53,240 Million generated in the Financial Year 2018-19 compared to INR 39,950 Million in the Financial Year 2017-18. For more information about the organization, please visit www.jubilantpharma.com.,

Jubilant Pharma Limited is a global integrated pharmaceutical company offering a wide range of products and services to its customers across geographies. Our business is organized into two segments - Specialty Pharmaceuticals and Generics & APIs. Jubilant Generics (JGL), a wholly-owned subsidiary of Jubilant Pharma, has Research & Development units in Noida and Mysore, India. JGL operates two manufacturing facilities in Mysore, Karnataka, and Roorkee, Uttarakhand, engaged in APIs and Dosage manufacturing, respectively. The Mysore manufacturing site, spread over 69 acres, is a USFDA approved facility producing APIs for global sales, with a focus on Lifestyle driven Therapeutic Areas like CVS and CNS. The Roorkee facility is state of the art, approved by multiple regulatory bodies, and operates on a B2B model for EU, Canada, and emerging markets. Backward-integrated manufacturing units are supported by around 500 research and development professionals based at Noida and Mysore. R&D activities include the development of new products in API and various dosage forms like Oral Solid, Sterile Injectable, Semi-Solids, Creams, and Liquids. In-house BA/BE studies are conducted at our 80-bed facility with global regulatory accreditations. JGL's Regulatory Affairs & IPR team ensures a unique portfolio of patents and product filings in regulatory and non-regulatory markets. The revenue of Jubilant Pharma has been on the rise, reaching INR 53,240 Million in the Financial Year 2018-19 compared to INR 39,950 Million in the Financial Year 2017-18. For more information about our organization, please visit www.jubilantpharma.com.,

Jubilant Pharma Limited is a global integrated pharmaceutical company that offers a diverse range of products and services to customers worldwide. The business is structured into two key segments: Specialty Pharmaceuticals and Generics & APIs. In the Specialty Pharmaceuticals segment, the company specializes in Radiopharmaceuticals, Contract Manufacturing of Sterile Injectable, Non-sterile & Allergy Therapy Products. The Generics & APIs segment focuses on Solid Dosage Formulations & Active Pharmaceutical Ingredients. Jubilant Generics (JGL) is a wholly-owned subsidiary of Jubilant Pharma, with Research & Development units located in Noida and Mysore, India. JGL operates manufacturing facilities in Mysore, Karnataka, and Roorkee, Uttarakhand, dedicated to APIs and Dosage manufacturing. The Mysore manufacturing site, spread over 69 acres, is USFDA approved and produces APIs for global distribution, with a focus on Lifestyle driven Therapeutic Areas such as CVS and CNS. The Roorkee facility is a state-of-the-art site approved by multiple regulatory bodies including USFDA, Japan PMDA, UK MHRA, TGA, WHO, and Brazil ANVISA, catering to B2B markets in EU, Canada, and emerging markets. Backward-integrated manufacturing units are supported by a team of 500 research and development professionals based in Noida and Mysore. The R&D team focuses on developing new products in API, Solid Dosage Formulations, Sterile Injectable products, Semi-Solids like Ointments, Creams, and Liquids. The company conducts all BA/BE studies in-house at an 80 Bed facility with global regulatory accreditations. JGL's Regulatory Affairs & IPR professionals manage a unique portfolio of patents and product filings for regulatory and non-regulatory markets. Jubilant Pharma has witnessed consistent revenue growth, with revenue reaching INR 53,240 Million in the Financial Year 2018-19, compared to INR 39,950 Million in the Financial Year 2017-18. For more information about the organization, please visit www.jubilantpharma.com.,

Jubilant Pharma Limited is a global integrated pharmaceutical company that offers a wide range of products and services to customers across various geographies. The business is organized into two segments: Specialty Pharmaceuticals and Generics & APIs. Specialty Pharmaceuticals segment includes Radiopharmaceuticals, Contract Manufacturing of Sterile Injectable, Non-sterile & Allergy Therapy Products. Generics & APIs segment comprises Solid Dosage Formulations & Active Pharmaceutical Ingredients. Jubilant Generics (JGL) is a wholly-owned subsidiary of Jubilant Pharma with Research & Development units in Noida and Mysore, India. It operates two manufacturing facilities in Mysore, Karnataka, and Roorkee, Uttarakhand, focusing on APIs and Dosage manufacturing. The Mysore manufacturing site, spread over 69 acres, is a USFDA approved facility catering to global sales with a portfolio concentrating on Lifestyle-driven Therapeutic Areas like CVS, CNS. The Roorkee facility is state-of-the-art and approved by multiple regulatory bodies including USFDA, Japan PMDA, UK MHRA, TGA, WHO, and Brazil ANVISA, following a B2B model for EU, Canada, and emerging markets. Both manufacturing units are backward-integrated and supported by approximately 500 research and development professionals in Noida and Mysore. R&D efforts include developing new products in API, Solid Dosage Formulations, Sterile Injectable, Semi-Solids Ointments, Creams, and Liquids. JGL's Regulatory Affairs & IPR professionals maintain a unique portfolio of patents and product filings in regulatory and non-regulatory markets. Jubilant Pharma's revenue has been consistently growing, reaching INR 53,240 Million during the Financial Year 2018-19 compared to INR 39,950 Million in the Financial Year 2017-18. For more information about the organization, please visit www.jubilantpharma.com.,

Jubilant Pharma Limited is a global integrated pharmaceutical company offering a wide range of products and services to its customers across geographies. The business is organized into two segments: Specialty Pharmaceuticals and Generics & APIs. Jubilant Generics (JGL), a wholly-owned subsidiary of Jubilant Pharma, operates Research & Development units in Noida and Mysore, India. The company has two manufacturing facilities - one in Mysore, Karnataka, and another in Roorkee, Uttarakhand - engaged in the production of APIs and Dosage manufacturing. The Mysore manufacturing location, spread over 69 acres, is a USFDA approved site specializing in manufacturing APIs for Lifestyle driven Therapeutic Areas such as CVS and CNS. It is a market leader in four APIs and among the top three players for three other APIs in its portfolio. On the other hand, the Roorkee facility is a state-of-the-art site approved by multiple regulatory bodies including USFDA, Japan PMDA, UK MHRA, TGA, WHO, and Brazil ANVISA. This facility focuses on a B2B model for EU, Canada, and emerging markets. Both manufacturing units are supported by approximately 500 research and development professionals based at Noida and Mysore. The R&D team works on developing new products in API, Solid Dosage Formulations of Oral Solid, Sterile Injectable, Semi-Solids Ointments, Creams, and Liquids. Additionally, all BA/BE studies are conducted in-house at an 80-bed facility with approvals from various regulatory authorities. JGL's Regulatory Affairs & IPR professionals ensure a unique portfolio of patents and product filings in regulatory and non-regulatory markets. Jubilant Pharma's revenue has shown a constant increase, reaching INR 53,240 Million in the Financial Year 2018-19 compared to INR 39,950 Million in the Financial Year 2017-18. For more information about the organization, please visit www.jubilantpharma.com.,

Jubilant Pharma Limited is a global integrated pharmaceutical company offering a wide range of products and services to customers across geographies. The business is structured into two segments: Specialty Pharmaceuticals and Generics & APIs. Specialty Pharmaceuticals includes Radiopharmaceuticals, Contract Manufacturing of Sterile Injectable, Non-sterile & Allergy Therapy Products. Generics & APIs includes Solid Dosage Formulations & Active Pharmaceutical Ingredients. Jubilant Generics (JGL) is a wholly-owned subsidiary of Jubilant Pharma with Research & Development units in Noida and Mysore, India. It operates manufacturing facilities in Mysore, Karnataka, and Roorkee, Uttarakhand, engaged in APIs and Dosage manufacturing, respectively. The Mysore manufacturing site, spread over 69 acres, is USFDA approved and focuses on Lifestyle driven Therapeutic Areas like CVS and CNS. It is a market leader in four APIs and among the top three players for three others. The Roorkee facility is state-of-the-art, approved by multiple regulatory bodies, and works on a B2B model for EU, Canada, and emerging markets. Both manufacturing units are supported by around 500 research and development professionals based at Noida and Mysore. The R&D focuses on developing new products in API, Solid Dosage Formulations, Sterile Injectable, Semi-Solids, Ointments, Creams, and Liquids. All BA/BE studies are conducted in-house at an 80 Bed facility with global regulatory accreditations. JGL's Regulatory Affairs & IPR professionals ensure a unique portfolio of patents and product filings in regulatory and non-regulatory markets. The revenue of Jubilant Pharma has been increasing, with INR 53,240 Million in the Financial Year 2018 -19 compared to INR 39,950 Million in 2017-18. For more information about the organization, please visit www.jubilantpharma.com.,

Jubilant Pharma Limited is a global integrated pharmaceutical company offering a wide range of products and services to customers across geographies. The business is organized into two segments - Specialty Pharmaceuticals and Generics & APIs. Jubilant Generics (JGL), a wholly-owned subsidiary of Jubilant Pharma, has Research & Development units in Noida and Mysore, India. JGL operates two manufacturing facilities in Mysore, Karnataka, and Roorkee, Uttarakhand, specializing in APIs and Dosage manufacturing. The Mysore manufacturing location, spread over 69 acres, is a USFDA approved site focusing on Lifestyle driven Therapeutic Areas such as CVS and CNS. It is a market leader in four APIs and amongst the top three players for three others. The Roorkee facility is a state-of-the-art site approved by USFDA, Japan PMDA, UK MHRA, TGA, WHO, and Brazil ANVISA, following a B2B model for EU, Canada, and emerging markets. Both manufacturing units are supported by around 500 research and development professionals based in Noida and Mysore. The R&D team works on developing new products in API, Solid Dosage Formulations of Oral Solid, Sterile Injectable, Semi-Solids Ointments, Creams, and Liquids. In-house BA/BE studies are conducted at an 80 Bed facility with multiple global regulatory accreditations. JGL's Regulatory Affairs & IPR professionals maintain a unique portfolio of patents and product filings in regulatory and non-regulatory markets. The revenue of Jubilant Pharma has been on a consistent rise, reaching INR 53,240 Million during the Financial Year 2018-19 compared to INR 39,950 Million in 2017-18. For more information about the organization, please visit www.jubilantpharma.com.,